XNASNVNO
Market cap58mUSD
Jan 08, Last price
3.36USD
1D
-0.88%
1Q
7.69%
IPO
-67.19%
Name
enVVeno Medical Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
101.05%
Rev. gr., 5y
-55.86%
Revenues
0k
Net income
-24m
L-3.24%
CFO
-19m
L+20.74%
Earnings
Feb 26, 2025
Profile
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 14,129 | 10,439 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (14,129) | (10,439) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (365) | ||||||||
Tax Rate | |||||||||
NOPAT | (14,129) | (10,074) | |||||||
Net income | (23,516) -3.24% | (24,304) 50.06% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 25,791 | ||||||||
BB yield | -40.79% | ||||||||
| Debt | |||||||||
Debt current | 676 | 314 | |||||||
Long-term debt | 2,466 | 3,118 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (43,270) | (35,612) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (18,858) | (15,619) | |||||||
CAPEX | (33) | (115) | |||||||
Cash from investing activities | (7,868) | (34,554) | |||||||
Cash from financing activities | 25,791 | ||||||||
FCF | (13,616) | (9,663) | |||||||
| Balance | |||||||||
Cash | 46,412 | 39,044 | |||||||
Long term investments | |||||||||
Excess cash | 46,412 | 39,044 | |||||||
Stockholders' equity | (130,036) | (106,520) | |||||||
Invested Capital | 177,976 | 146,965 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 12,301 | 11,230 | |||||||
Price | 5.14 0.78% | 5.10 -22.61% | |||||||
Market cap | 63,227 10.40% | 57,273 0.13% | |||||||
EV | 19,957 | 21,661 | |||||||
EBITDA | (13,583) | (9,914) | |||||||
EV/EBITDA | |||||||||
Interest | 263 | ||||||||
Interest/NOPBT | |||||||||